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The use of illicit heroin is a challenge in South Africa (SA) and 
worldwide. The World Drug Report 2019 states that 17.3% of 
people treated for a drug problem in SA use heroin as their 
primary drug of choice.[1] Globally, and in SA, cannabis is the most 
commonly used non-regulated drug, while opioids are associated 
with the most negative health impacts.[2] Opioids were associated 
with 76% of drug-related deaths in 2015.[2] Approximately 0.7% of 
the global population aged 15 - 64 years were estimated to have 
used opioids for non-prescription purposes in 2016.[2] In SA, and 
more specifically in Tshwane, heroin is locally known as nyaope, 
which is smoked or snorted, and might be mixed with cannabis and 
various other ingredients.[3] The management of opioid use disorder 
(OUD) involves a comprehensive approach. The World Health 
Organization (WHO) advocates an evidence-based approach with 
opioid substitution therapy (OST) as the recommended treatment 
for the management of OUD.[4] Methadone, a full µ-opioid receptor 
agonist, and buprenorphine, a partial µ-opioid receptor agonist 
(with or without naloxone, an opioid antagonist), are included in the 
WHO’s essential drug list for OST.[5]
In 2016, in response to the growing prevalence of heroin use 
in Tshwane, in a joint initiative the City of Tshwane and the 
Department of Family Medicine, University of Pretoria developed 
the Community Oriented Substance Use Programme (COSUP).[6] 
COSUP was based on the principles of community-orientated 
primary care.[7] The programme follows a harm-reduction approach, 
offering OST, as well as psychosocial support and needle syringe 
programmes to outpatients at 17 different sites around the city.[8] Sites 
are situated in the inner city of Tshwane, as well as in surrounding 
suburban and periurban areas. OST offered to those with an OUD 
primarily includes methadone (~80%). Buprenorphine-naloxone is 
also offered, but was not the focus of this research.
In COSUP, the OST dosing approach includes daily directly 
observed treatment (DOT) with take-home doses on weekends, 
and once stable, OST is entrusted to a family member or support 
person to take home for longer periods of time. Before initiation on 
methadone, each patient has a psychosocial evaluation, a medical 
history is taken and an examination is done. Participants with a 
high-risk opioid use score (≥27) on the Alcohol, Smoking and 
Substance Involvement Screening Test (ASSIST 3.0),[9] who are able 
to attend daily at a COSUP site and who do not have any medical 
contraindications to methadone, are initiated on OST. The ASSIST 3.0 
is a tool developed by the WHO for primary healthcare settings 
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associated with at least 6 months’ retention for 575 participants from December 2016 to September 2018 were analysed.
Results. There were 91.3% males, 86.4% South Africans and 85.9% black Africans, with a median age of 30 years. At baseline, the majority 
were injecting heroin (55.5%) and were provided with free methadone (59.3%). The median dose of methadone at 6 months or on leaving 
the programme was 20 mg; 38.4% of participants were retained for at least 6 months. Of those not retained, the median duration on 
methadone was 56 days, whereas for those retained for at least 6 months, the median number of days on methadone were 254. After 
adjusting for sex and age, participants receiving methadone doses <50 mg had lower odds of being retained (0 - 20 mg: adjusted odds ratio 
(aOR) 0.25; p=0.002; 95% confidence interval (CI) 0.10 - 0.61; >20 - 40 mg: aOR 0.20; p<0.001; 95% CI 0.08 - 0.49) than those administered 
≥50 mg. Participants who received free methadone had 3.75 the odds of being retained than those buying it themselves (p<0.001; 
95% CI 2.47 - 5.70). Participants treated in the inner city had 5.19 the odds of being retained than those in a suburban setting (p<0.001; 
95% CI 2.99 - 9.03). Compared with black African participants, white participants had 3.39 the odds of being retained (p=0.001; 
95% CI 1.64 - 7.00). Injecting heroin users had 0.63 the odds of being retained (p=0.032; 95% CI 0.41 - 0.96).
Conclusions. To maximise retention on OST, methadone should be free, with maintenance doses >50 mg. Reasons for lower retention 
among participants from periurban settings, those who inject and those from previously disadvantaged racial groups need to be explored, 
and findings used to inform programming. 
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where hazardous and harmful substance use among patients may go 
undetected. It is an 8-item questionnaire that determines a risk score 
for each substance used, i.e. low, moderate or high risk (the risk score 
determines the most appropriate intervention for that level of use).[9]
Methadone is prescribed by a medical doctor, and DOT is 
performed by a clinical associate. Patients are slowly up-titrated from 
their starting dose (average 10 - 30 mg/day, with a standard starting dose of 
20 mg), until they reach a maintenance dose, over 18 - 32 days. According 
to COSUP’s standard operating procedure for OST, methadone should 
be increased by 5 - 10 mg every 3 - 4 days, until a maintenance 
dose is reached. The dose is increased according to the patient’s 
symptoms or experience of side-effects and clinician experience as 
per recommendations by the WHO.[4] The dosage for self-funded 
patients is limited by their ability to pay.
After a need-based assessment, which includes medical and 
psychosocial investigations with home visits and assessment of 
either the financial ability to cover methadone costs, or urgency for 
which the client needs OST, those who are unable to pay are given 
methadone, funded by COSUP.
Internationally, it has been shown that prolonged methadone 
use within an OST programme decreases HIV and hepatitis C 
transmission, leads to a decrease in criminal activity and to an 
improvement in antiretroviral treatment (ART) adherence in people 
living with HIV.[10,11] It is therefore important to retain patients in OST 
programmes. A factor associated with such retention is an adequate 
daily dose of methadone (60 - 120 mg).[3,4,12-14] Other factors positively 
associated with being retained on OST include access to free or 
affordable OST medications, age >35 years, female sex, a higher 
level of education and being employed. Factors negatively associated 
with retention are the presence of a criminal record, serious mental 
illness and living in a rural area, where health services may be less 
accessible.[13,15-17] A study of a pilot programme in Western Cape 
Province, using time-limited (3 months) buprenorphine-naloxone 
v. no buprenorphine-naloxone, showed that patients receiving the 
former were more likely to be retained in a substance use treatment 
programme than those not on the medication.[18]
The aim of this research was to determine selected socio-
demographic and substance use treatment factors associated 
with retention for at least 6 months among participants receiving 
methadone as part of OST in COSUP.
Methods
This was a retrospective cohort study, including all patients enrolled 
into COSUP and initiated on methadone from December 2016 to 
September 2018. Participants from 8 COSUP and satellite sites were 
included, with complete sampling. 
Inclusion criteria included: patients enrolled into COSUP at 1 of 
8 sites or satellite sites during the study period, who signed consent 
and were started on methadone. Exclusion criteria included: COSUP 
patients not on OST or who were on buprenorphine (with/without 
naloxone). Patients who were receiving methadone at the end of the 
study period, but had not yet been using it for 6 months, were also 
excluded.
Data were abstracted from two sources. The first source comprised 
COSUP OST records kept by each site and updated every month. 
Data extracted were sex, location (inner city v. suburban), method of 
drug use at OST initiation, OST initiation date, methadone dose when 
starting and at 6 months or on leaving COSUP if before 6 months, 
total days on methadone, methadone funding source and termination 
date. The second data source comprised electronic patient records 
from Synaxon (Synaxon, SA), a health record database contracted 
by the Department of Family Medicine, University of Pretoria. Data 
extracted from this source were age, population group (black, white, 
coloured or Asian/Indian) and nationality. After using medical record 
numbers to connect patients to their records in both data sources and 
combining these, each participant was allocated a unique identifier that 
could not be connected to any identifying information. The data were 
imported into Stata 15 (StataCorp., USA)[19] for analysis. 
Descriptive statistics (mean, median, proportion, standard deviation 
(SD) and interquartile range (IQR))) were used to describe the 
population. The outcome variable was ‘retained’, where participants 
were defined as retained if receiving methadone for ≥6 months after 
initiation date. 
Continuous variables (e.g. age and methadone dosage) were 
explored graphically. An ordinal categorical variable for methadone 
dose was generated. The lower two categories were 0 - 20 mg and >20 - 
40 mg, according to the most common dose used in participants. The 
highest category was 50 - 100 mg. No participants received 41 - 49 mg 
methadone and, as such, this bracket was excluded. Ideally, the highest 
category should have been 80 - 120 mg, which is the international 
benchmark,[4] but due to a limited number of participants in this group, 
a dose of ≥50 mg was decided on as an appropriate marker to compare 
a higher dose with lower doses in the majority of participants.
Univariate analysis was performed for all variables. A p-value ≤0.25 
was used to identify variables for inclusion in the multivariate model.[20] 
Bivariate analysis with Pearson’s χ2 -squared tests was performed to 
review associations between independent categorical variables.
A hierarchical backwards stepwise approach was used in trimming 
the multivariate model with likelihood ratio tests. Variables were kept 
in the model if p≤0.2[21] or if they were known independent factors 
influencing retention. 
Ethical approval
The research was approved by the Health Sciences Research Ethics 
Committee, University of Pretoria (ref. no. 176/2019). Informed 
consent was obtained by COSUP staff when participants entered the 
programme. Participants did not receive remuneration on admission 
to COSUP.
Results
During the study period, 805 patients were initiated on methadone 
across the 8 sites. All patients provided informed consent for research 
participation. At the end of the study period, 230 patients had not yet 
received OST for 6 months. 
Therefore, 575 participants were included in the analysis (71.4%; 
575/805), and 221 (38.4%) received methadone for at least 6 months. 
The median duration for those retained on methadone was 254 
(IQR 215 - 352) days. The retained participants were 89.6% (n=198) 
male, 80.5% (n=178) black African and 80.5% (n=178) South African. 
The most common method of drug use for this group was smoking 
(55.7%; n=123). 
The median age of participants in the not-retained group was 30 
(IQR 27 - 34) years, with a median methadone dose of 20 (IQR 20 - 
30) mg at the time of leaving COSUP. The median duration for those 
not retained was 56 (IQR 27 - 109) days. Participants not retained 
were 92.4% (n=327) male, 89.3% (n=316) black African and 90.1% 
(n=319) South African. Most (55.4%; n=196) participants reported 
smoking heroin at initiation. Further details are set out in Table 1.
Results for univariate and multivariate models after binary logistic 
regression for retained participants as the outcome are summarised 
in Table 2. For the final multivariate model, when adjusting for age, 
sex and injecting status, participants who were COSUP funded 
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Table 1. Characteristics of OST participants by retention at 6 months, Tshwane, SA, December 2016 - September 2018 (N=575)
Variable Not retained Retained Total
Participants, n (%) 354 (61.6) 221 (38.4) 575 (100)
Age (years), median (IQR) 30 (27 - 34) 30 (27 - 35) 30 (27 - 34)
Sex, n (%)
Male 327 (92.4) 198 (89.6) 525 (91.3)
Female 27 (7.6) 23 (10.4) 50 (8.7)
Nationality, n (%)
South African 319 (90.1) 178 (80.5) 497 (86.4)
Foreign 35 (9.9) 43 (19.5) 78 (13.6)
Population group, n (%)
Black 316 (89.3) 178 (80.5) 494 (85.9)
White 21 (5.9) 27 (12.2) 48 (8.3)
Coloured 12 (3.4) 15 (6.8) 27 (4.7)
Indian 5 (1.4) 1 (0.5) 6 (1.0)
Methadone dose (mg), median (IQR)* 20 (20 - 30) 30 (20 - 40) 20 (20 - 30)
Methadone (days), median (IQR) 56 (27 - 109) 254 (215 - 352) -
Funding, n (%)
COSUP funded 169 (47.7) 172 (77.8) 341 (59.3)
Self-funded 185 (52.3) 49 (22.2) 234 (40.7)
Method of heroin use at initiation, n (%)
Smoke 196 (55.4) 123 (55.7) 319 (55.5)
Inject 158 (44.6) 98 (44.3) 256 (44.5)
OST = opioid substitution therapy; SA = South Africa; IQR = interquartile range; COSUP = Community Oriented Substance Use Programme.
*Median methadone at 6 months or at time of exiting programme if before 6 months.
Table 2. Logistic regression results for OST retention, Tshwane, SA, December 2016 - September 2018 
         Univariate OR                      Multivariate aOR, N=575
Covariables OR p-value* aOR p-value† 95% CI
Funding 
Self-funded Ref.
COSUP funded 3.84 <0.001 3.75 <0.001 2.47 - 5.70
Location
Suburban Ref.
Inner city 4.72 <0.001 5.19 <0.001 2.99 - 9.03
Dose category, mg
≥50 Ref.
0 - 20 0.17 <0.001 0.25 0.002 0.10 - 0.61
>20 - 40 0.23 <0.001 0.20 <0.001 0.08 - 0.49
Nationality
South African Ref.
Foreign 2.20 0.001 - - -
Population group
Black African Ref.
White 2.28 0.007 3.39 0.001 1.64 - 7.00
Coloured 2.22 0.045 2.30 0.062 0.96 - 5.51
Indian 0.36 0.346 0.39 0.403 0.04 - 3.58
Age, years 1.02 0.088 1.01 0.470 0.98 - 1.04
Sex
Male Ref.
Female 1.41 0.254 0.80 0.526 0.40 - 1.60
Injecting 0.99 0.946 0.63 0.032 0.41 - 0.96
OST = opioid substitution therapy; SA = South Africa; OR = odds ratio; aOR = adjusted odds ratio; CI = confidence interval; Ref. = reference; COSUP = Community Oriented Substance Use 
Programme.
*p-value ‒ for the χ2 test.
†p-value ‒ for the Wald (z) test.
Note: Interactions were considered and excluded owing to non-significant p-values and likelihood-ratio tests.
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had 3.75 the odds of being retained compared with those who were 
self-funded (p<0.001; 95% confidence interval (CI) 2.48 - 5.70). 
Those treated in the inner city had 5.19 the odds of being retained 
compared with those who were treated in suburban sites (p<0.001; 
95% CI 2.99 - 9.03). Compared with methadone doses ≥50 mg, those 
receiving 0 - 20 mg had 0.25 the odds of being retained, and those 
on >20 - 40 mg had 0.20 the odds of being retained (p=0.002; 
95% CI 0.10 - 0.61, and p<0.001; 95% CI 0.08 - 0.49, respectively). 
Compared with black African participants, white participants had 
3.39 the odds of being retained (p=0.001; 95% CI 1.64 - 7.00). 
Participants who reported injecting heroin at initiation had 0.63 the 
odds of being retained compared with those who smoked heroin 
(p=0.032; 95% CI 0.41 - 0.96).
Discussion 
Factors associated with retention in COSUP were access to funded 
methadone, methadone dose ≥50 mg, accessing treatment in the inner 
city, and white population group. Injecting drug use was negatively 
associated with retention. Age and sex were not associated with retention.
In accordance with the international literature,[13,15] the availability 
of affordable (in our case, free) methadone was shown to play a 
significant role in retaining patients in OST programmes. The results 
show that patients receiving programme-funded methadone have 
3.75 times the odds of staying on methadone for at least 6 months 
than those who buy their own methadone. This may be as a result 
of patients having limited funds and competing priorities, such as 
housing or food, on which to spend their money.[22]
The majority of South Africans access healthcare through the 
public health system, with 71.5% of households primarily accessing 
such facilities for their health needs.[23] Care at government primary 
healthcare facilities, including prescription medication, is free of 
charge. Methadone, however, is not yet on the Essential Medicines 
List (EML)[24] for use at the primary care level for maintenance. The 
cost of methadone in SA is 10 - 20 times more than the average cost 
in other middle-income countries[25] (ZAR0.81 - ZAR1.04 per mg, 
or ZAR40.50 - ZAR52.00 for a daily dose of 50 mg).[26] Few people 
who use heroin are able to afford this expense. Making methadone 
accessible at a primary care level to people who use drugs, would 
assist them in regaining functional lives, with an overall improvement 
in their quality of life.[27] 
Although almost none of the study participants was on optimal 
methadone doses according to WHO guidelines,[4] and even local 
guidelines,[3] it was clear that those administered doses <50 mg had 
lower odds of being retained. Lower doses of methadone might 
increase the likelihood of the co-use of illicit opioids[28,29] to prevent 
withdrawal symptoms. Furthermore, suboptimal doses do not provide 
adequate receptor coverage, which is needed to reduce cravings.[25] As 
such, it is unsurprising that participants who were not retained were 
more commonly on lower doses of methadone. Programmatically, 
one should take cognisance of this important outcome. International 
and local guidelines,[3,4] as well as COSUP’s OST standard operating 
procedure document, recommend that methadone be increased 
by 5 - 10 mg every 3 - 5 days until a maintenance dose is reached. 
The literature shows that the optimal maintenance dose is most 
commonly between 60 mg and 120 mg daily.[3,4] The group not 
retained received methadone for a median duration of 56 (IQR 27 - 
109) days. For that group, the median methadone dose was 20 
(IQR 20 - 30) mg, which is the recommended starting dose. Given 
that the majority of patients should have reached maintenance 
around 32 days if up-titrated according to guidelines, it points to the 
importance of intentional up-titration until maintenance is reached. 
Even in the retained group, who were on methadone for a median 
of 254 (IQR 215 - 352) days, the majority of methadone doses 
remained below the recommended maintenance dose, with those on 
≥50 mg having greater odds of being retained. Patients are unlikely 
to remain in OST programmes if they do not receive appropriate 
doses. Over time, as they find they still need heroin to manage their 
cravings and because of withdrawal symptoms, they may lose faith 
in the programme and drop out. Furthermore, the time required to 
mobilise resources to secure methadone and/or heroin may make it 
challenging to access daily doses.
Reasons for prescribing suboptimal methadone dosing need to be 
explored through further research. Hypotheses from the literature 
are discussed below. Firstly, there is the fear of liability, where 
prescribers were concerned about possible overdose, especially with 
co-use of heroin during the first few weeks of methadone initiation.[30] 
Prescribers may also not have had adequate training or experience 
in prescribing or managing patients on methadone and are therefore 
careful with prescription of doses.[31] Secondly, there are unclear 
management goals, where a poor understanding of harm reduction 
may result in scepticism towards the need to prescribe methadone 
for long periods, as well as weaning patients off methadone to save 
them from daily clinic visits.[30] Thirdly, there may be poor patient-
healthcare worker communication, where patients do not feel free to 
admit co-use of a drug(s), and the prescriber is therefore not aware 
that the current methadone dose is not yet effective. Conversely, the 
prescriber may feel that the patient is trying to manipulate higher 
doses for personal gain, unrelated to the management of OUD, and 
therefore refuse to increase the dose.[30] Finally, there are side-effects 
with higher doses, where prescribers found that participants had 
more side-effects, such as constipation, erectile dysfunction, sleeping 
problems and menstrual cycle irregularities, and therefore tapered 
the dose to mitigate these effects.[30] 
It is interesting that participants frequenting inner-city sites have 
higher odds of being retained than those in suburban sites. Various 
hypotheses may be put forward. It may be due to the high prevalence 
of homelessness in the inner city,[22] with participants motivated to 
access care and escape from their difficult circumstances. People 
living in suburban areas may be more likely to live at home. However, 
homelessness is not restricted to the inner city and further research 
is required in this regard. Another hypothesis is that the inner city 
is geographically a smaller area, which is fairly well serviced by 
3 COSUP sites. It is possibly easier for participants to access 
these sites than for those in suburban areas, who may need to 
use transport, such as minibus taxis, to visit a site. It is possible 
that people from disadvantaged communities may have barriers 
to accessing care, including financial difficulties, where high costs 
associated with public transport, together with a potential loss of 
income associated with visiting a site, may deter participants from 
accessing care.[32] While COSUP has attempted to ameliorate this 
situation by establishing sites in disadvantaged suburban areas, these 
cover a large geographical area. Another hypothesis is that there has 
already been harm reduction for people who have been using drugs 
in the city centre for a number of years – they may be more sensitised 
to this and more willing to access care.[33]
The mean methadone dose for those in the inner city was 37.8 mg 
and for suburban areas 24.2 mg, with 55.9% injectors in the inner 
city and 41.6% injectors in the suburban area. This higher average 
dose at inner-city sites than at suburban sites may be the reason for 
better retention at the former. However, with the injecting of heroin 
negatively related to retention, this may not be true and should be 
further investigated.
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The majority of participants who are enrolled into COSUP are black 
Africans. Nonetheless, the results showed that white participants 
were more likely to be retained. The results for the coloured and 
Indian population groups were not significant, possibly because of 
the small number in each of these groups. The result may speak to 
the persisting disparity and socioeconomic inequality that are linked 
to race in SA, where white people have relatively better access to 
resources and are more empowered to use them than many of the 
other population groups.[34] However, studies in the USA showed that 
communities generally view white drug users with more sympathy, 
assuming a valid reason for their drug use. There is a greater 
willingness to assist them with healthcare and resources than their 
counterparts from other racial groups.[35] However, it is difficult 
to draw conclusions around this result, owing to factors regarding 
health inequality and other socioeconomic factors not examined in 
this study, which are discussed below under study limitations. 
This research contributes to the body of knowledge surrounding 
illicit opioid use in SA. It will assist to enhance retention in 
OST programmes locally and beyond. Methadone should be made 
available on the primary care EML for OST as maintenance – at an 
affordable price. 
Due to the secondary nature of the data, there were many areas that 
were not available for analysis. A follow-up study should take place 
investigating factors such as level of education, employment, social 
support systems, criminal records and other psychosocial factors, 
specifically in the SA context, which may contribute to retention. 
Going forward, information around education, employment 
and other psychosocial factors should be included as part of the 
programme data. 
Study strengths and limitations
Strengths of this study include that it is an important and relevant 
topic in the SA context and unique in identifying issues within the 
SA health system regarding data that have not been available in the 
past. Results may allow for important service planning for this group 
of people.
Limitations of the study include that, using an approach of the last 
observation carried forward, and that all starting doses of methadone 
are low, it may be that had patients not dropped out, they would have 
ended on an optimal (higher) dose. This may introduce confounding 
but, given that there was an adequate number of days that patients 
received methadone for the majority to be on maintenance doses, this 
remains an important observation. A further limitation mentioned 
in relation to the differing retention among different race groups is 
that informed conclusions cannot be drawn around reasons for the 
result. While it is common practice to adjust for sociodemographic 
characteristics in multivariate analysis, important socioeconomic 
factors, such as dwelling, employment and education, as well as 
those around health inequality and different ethical views regarding 
substance use disorders, were not collected in this secondary dataset. 
Therefore, further research would be required to adequately delve 
into the reason for this result.
Conclusions
In this study, methadone dose, affordable methadone (free), treatment 
in the inner city and mode of heroin use were related to retention. 
To improve retention, service improvements should include 
actively providing free methadone to people with OUD, and ensuring 
that doses comply with international standards. The introduction of 
methadone in the primary care EML would go a long way towards 
providing methadone to those in need. Furthermore, intentional 
up-titration of methadone, as recommended in guidelines, should be 
a priority to ensure that maintenance doses are reached in a safe and 
timely manner, with a knock-on effect of higher doses, thus aligning 
with international standards. People who inject opioids should 
remain a priority in methadone maintenance programmes, focusing 
on the abovementioned areas to keep them retained. More research is 
required to understand why inner-city participants are more likely to 
be retained in treatment, as well as to better understand the difference 
in retention with regard to different racial groups. 
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